Title |
Pomalidomide in the treatment of multiple myeloma: design, development and place in therapy
|
---|---|
Published in |
Drug Design, Development and Therapy, August 2017
|
DOI | 10.2147/dddt.s115456 |
Pubmed ID | |
Authors |
Rafael Ríos-Tamayo, Agustín Martín-García, Carolina Alarcón-Payer, Dolores Sánchez-Rodríguez, Ana María del Valle Díaz de la Guardia, Carlos Gustavo García Collado, Alberto Jiménez Morales, Manuel Jurado Chacón, José Cabeza Barrera |
Abstract |
Multiple myeloma is a very heterogeneous disease with variable survival. Despite recent progress and the widespread use of new agents, patients with relapsed and refractory disease have a poor outcome. Immunomodulatory drugs play a key role in both the front-line and the relapsed/refractory setting. The combination of pomalidomide (POM) and dexamethasone is safe and effective in relapsed and refractory patients, even in those with high-risk cytogenetic features. Furthermore, it can be used in most patients without the need to adjust according to the degree of renal failure. In order to further improve the results, POM-based triplet therapies are currently used. This article highlights the most relevant issues of POM and POM-based combinations in the relapsed/refractory multiple myeloma setting, from a pharmacological and clinical point of view. |
X Demographics
Geographical breakdown
Country | Count | As % |
---|---|---|
United States | 1 | 50% |
Spain | 1 | 50% |
Demographic breakdown
Type | Count | As % |
---|---|---|
Scientists | 1 | 50% |
Practitioners (doctors, other healthcare professionals) | 1 | 50% |
Mendeley readers
Geographical breakdown
Country | Count | As % |
---|---|---|
Unknown | 52 | 100% |
Demographic breakdown
Readers by professional status | Count | As % |
---|---|---|
Student > Bachelor | 9 | 17% |
Student > Ph. D. Student | 8 | 15% |
Other | 7 | 13% |
Researcher | 7 | 13% |
Lecturer | 2 | 4% |
Other | 4 | 8% |
Unknown | 15 | 29% |
Readers by discipline | Count | As % |
---|---|---|
Medicine and Dentistry | 10 | 19% |
Biochemistry, Genetics and Molecular Biology | 8 | 15% |
Chemistry | 6 | 12% |
Pharmacology, Toxicology and Pharmaceutical Science | 4 | 8% |
Nursing and Health Professions | 2 | 4% |
Other | 7 | 13% |
Unknown | 15 | 29% |